To the Editor Relapse prevention is paramount in managing schizophrenia.1 Leucht et al2 conducted a meta-analysis of randomized clinical trials comparing the association between different antipsychotic maintenance doses and risk of relapse and rehospitalization in individuals with schizophrenia by generating efficacy-related dose-response curves. Prevention of relapse and rehospitalization increased with up to 5 mg/d risperidone equivalent. Higher doses conferred little further advantage for reducing relapse or rehospitalization, but were associated with higher intolerability-related dropout rates.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Højlund M, Haddad PM, Correll CU. Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA Psychiatry. Published online November 24, 2021. doi:10.1001/jamapsychiatry.2021.3452
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.